Roy N. Alcalay

Roy N. Alcalay

Auto-generated profile, based on publicly available information

Roy N. Alcalay

Department of Neurology, Columbia University Irving Medical Center

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2015 in Brain
Verified
Journal Article
Open access
PDF file
RARoy N. Alcalay
Roy N. Alcalay
OLOren A. Levy
Oren A. Levy
CWCheryl H. Waters
Cheryl H. Waters
SFStanley Fahn
Stanley Fahn
BFBlair Ford
Blair Ford
XZXiaokui Zhang
Xiaokui Zhang
Glucocerebrosidase (GBA) mutations have been associated with Parkinson’s disease in numerous studies. However, it is unknown whether the increased risk of Parkinson’s disease in GBA carriers is due to a loss of glucocerebrosidase enzymatic activity. We measured glucocerebrosidase enzymatic activity in dried blood spots in patients with Parkinson's disease (n = 517) and controls (n = 252) with and without GBA mutations. Participants were recruited from Columbia University, New York, and fully sequenced for GBA mutations and genotyped for the LRRK2 G2019S mutation, the most common autosomal dominant mutation in the Ashkenazi Jewish population. Glucocerebrosidase enzymatic activity in dried blood spots was measured by a mass spectrometry-based assay and compared among participants categorized by GBA mutation status and Parkinson’s disease diagnosis. Parkinson’s disease patients were more likely than controls to carry the LRRK2 G2019S mutation (n = 39, 7.5% versus n = 2, 0.8%, P < 0.001) and GBA mutations or variants (seven homozygotes and compound heterozygotes and 81 heterozygotes, 17.0% versus 17 heterozygotes, 6.7%, P < 0.001). GBA homozygotes/compound heterozygotes had lower enzymatic activity than GBA heterozygotes (0.85 µmol/l/h versus 7.88 µmol/l/h, P < 0.001), and GBA heterozygotes had lower enzymatic activity than GBA and LRRK2 non-carriers (7.88 µmol/l/h versus 11.93 µmol/l/h, P < 0.001). Glucocerebrosidase activity was reduced in heterozygotes compared to non-carriers when each mutation was compared independently (N370S, P < 0.001; L444P, P < 0.001; 84GG, P = 0.003; R496H, P = 0.018) and also reduced in GBA variants associated with Parkinson’s risk but not with Gaucher disease (E326K, P = 0.009; T369M, P < 0.001). When all patients with Parkinson’s disease were considered, they had lower mean glucocerebrosidase enzymatic activity than controls (11.14 µmol/l/h versus 11.85 µmol/l/h, P = 0.011). Difference compared to controls persisted in patients with idiopathic Parkinson’s disease (after exclusion of all GBA and LRRK2 carriers; 11.53 µmol/l/h, versus 12.11 µmol/l/h, P = 0.036) and after adjustment for age and gender (P = 0.012). Interestingly, LRRK2 G2019S carriers (n = 36), most of whom had Parkinson’s disease, had higher enzymatic activity than non-carriers (13.69 µmol/l/h versus 11.93 µmol/l/h, P = 0.002). In patients with idiopathic Parkinson’s, higher glucocerebrosidase enzymatic activity was associated with longer disease duration (P = 0.002) in adjusted models, suggesting a milder disease course. We conclude that lower glucocerebrosidase enzymatic activity is strongly associated with GBA mutations, and modestly with idiopathic Parkinson’s disease. The association of lower glucocerebrosidase activity in both GBA mutation carriers and Parkinson’s patients without GBA mutations suggests that loss of glucocerebrosidase function contributes to the pathogenesis of Parkinson’s disease. High glucocerebrosidase enzymatic activity in LRRK2 G2019S carriers may reflect a distinct pathogenic mechanism. Taken together, these data suggest that glucocerebrosidase enzymatic activity could be a modifiable therapeutic target.

26 March 2012 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
MPMarkos Poulopoulos
Markos Poulopoulos
OLOren A. Levy
Oren A. Levy
RARoy N. Alcalay
Roy N. Alcalay

1 May 2012 in Neurology
Verified
Journal Article
Closed access
PDF file
RAR N Alcalay
R N Alcalay
ECE. Caccappolo
E. Caccappolo
HMH. Mejia-Santana
H. Mejia-Santana
MTM.-X. Tang
M.-X. Tang
LRL. Rosado
L. Rosado
KMK. Marder
K. Marder
Objective: To assess the cognitive phenotype of glucocerebrosidase (GBA) mutation carriers with early-onset Parkinson disease (PD). Methods: We administered a neuropsychological battery and the University of Pennsylvania Smell Identification Test (UPSIT) to participants in the CORE-PD study who were tested for mutations in PARKIN, LRRK2, and GBA. Participants included 33 GBA mutation carriers and 60 noncarriers of any genetic mutation. Primary analyses were performed on 26 GBA heterozygous mutation carriers without additional mutations and 39 age- and PD duration–matched noncarriers. Five cognitive domains, psychomotor speed, attention, memory, visuospatial function, and executive function, were created from transformed z scores of individual neuropsychological tests. Clinical diagnoses (normal, mild cognitive impairment [MCI], dementia) were assigned blind to genotype based on neuropsychological performance and functional impairment as assessed by the Clinical Dementia Rating (CDR) score. The association between GBA mutation status and neuropsychological performance, CDR, and clinical diagnoses was assessed. Results: Demographics, UPSIT, and Unified Parkinson9s Disease Rating Scale–III performance did not differ between GBA carriers and noncarriers. GBA mutation carriers performed more poorly than noncarriers on the Mini-Mental State Examination (p = 0.035), and on the memory (p = 0.017) and visuospatial (p = 0.028) domains. The most prominent differences were observed in nonverbal memory performance (p < 0.001). Carriers were more likely to receive scores of 0.5 or higher on the CDR (p < 0.001), and a clinical diagnosis of either MCI or dementia (p = 0.004). Conclusion: GBA mutation status may be an independent risk factor for cognitive impairment in patients with PD.

7 February 2012 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
RARoy N. Alcalay
Roy N. Alcalay
YGYian Gu
Yian Gu
HMHelen Mejia‐Santana
Helen Mejia‐Santana
LCLucien Cote
Lucien Cote
KMKaren S. Marder
Karen S. Marder
NSNikolaos Scarmeas
Nikolaos Scarmeas

1 June 2014 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
RARoy N. Alcalay
Roy N. Alcalay
TDTama Dinur
Tama Dinur
TQTimothy Quinn
Timothy Quinn
KSKarina Sakanaka
Karina Sakanaka
OLOren Levy
Oren Levy
AZAri Zimran
Ari Zimran
Mutations in the glucocerebrosidase (GBA) gene have emerged as a common risk factor for the development of Parkinson disease (PD). This association was originally reported in case reports and case series involving patients with Gaucher disease (GD),1,2 an autosomal recessive lysosomal storage disease resulting from mutations in both alleles of GBA. Gaucher disease is the most common genetic disorder in the Ashkenazi Jewish (AJ) population. Among AJ individuals, most patients with GD carry at least 1 N370S allele, a missense mutation associated with type 1 GD, the milder nonneuronopathic form. Glucocerebrosidase heterozygosity is also associated with PD based on case-control studies comparing mutation frequency in patients with PD and control participants in different ethnic groups.1,3-10 Among patients with PD, at least 15% of AJ individuals and 3% of non-AJ individuals carry 1 of the 2 most common GBA mutations (N370S and L444P).7 A multicenter analysis estimated the odds ratio for carrying a GBA mutation in patients with PD vs control participants at 5.43 (95% CI, 3.89-7.57).7 However, data on the reverse association—the risk for PD in GBA heterozygotes—have been limited and widely variable, with penetrance estimations between 10.9% and 29.7% by 80 years of age.11-13 Furthermore, it is unclear whether the risk for PD is different among those carrying 2 mutant GBA alleles (ie, patients with GD) and those with 1 mutant allele (heterozygote carriers).

8 June 2018 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Closed access
PDF file
ZGZiv Gan-Or
Ziv Gan-Or
CLChristopher Liong
Christopher Liong
RARoy N. Alcalay
Roy N. Alcalay